- Previous Close
5.84 - Open
5.84 - Bid --
- Ask --
- Day's Range
5.84 - 5.85 - 52 Week Range
3.16 - 14.43 - Volume
238,299 - Avg. Volume
1,251,996 - Market Cap (intraday)
224.092M - Beta (5Y Monthly) 0.94
- PE Ratio (TTM)
-- - EPS (TTM)
-3.06 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.53
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS systems. It also offers Senza HFX iQ platform that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, the company provides HFX AdaptivAI, a pain management platform that powers the HFX iQ SCS system, as well as surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is based in Redwood City, California.
nevro.comRecent News: NVRO
View MorePerformance Overview: NVRO
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVRO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVRO
View MoreValuation Measures
Market Cap
224.09M
Enterprise Value
182.72M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.53
Price/Book (mrq)
0.97
Enterprise Value/Revenue
0.45
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-27.77%
Return on Assets (ttm)
-9.95%
Return on Equity (ttm)
-43.29%
Revenue (ttm)
408.52M
Net Income Avi to Common (ttm)
-113.44M
Diluted EPS (ttm)
-3.06
Balance Sheet and Cash Flow
Total Cash (mrq)
292.53M
Total Debt/Equity (mrq)
108.86%
Levered Free Cash Flow (ttm)
-4.77M